Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0502
-0.0006 (-1.18%)
At close: Oct 31, 2025
Adaptimmune Therapeutics Revenue
Adaptimmune Therapeutics had revenue of $13.68M in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.
Revenue (ttm)
65.09M
Revenue Growth
-53.99%
P/S Ratio
0.21
Revenue / Employee
128.63K
Employees
506
Market Cap
13.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 178.03M | 117.75M | 195.34% |
| Dec 31, 2023 | 60.28M | 33.13M | 122.05% |
| Dec 31, 2022 | 27.15M | 21.00M | 341.50% |
| Dec 31, 2021 | 6.15M | 2.19M | 55.36% |
| Dec 31, 2020 | 3.96M | 2.84M | 252.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Federal National Mortgage Association | 28.89B |
| Federal Home Loan Mortgage | 22.97B |
| First National of Nebraska | 1.89B |
| Central Bancompany | 914.42M |
| Wilson Bank Holding Company | 197.85M |
| IPE Universal | 17.33M |
| Jingbo Technology | 2.28M |
| Alpine Auto Brokers | 129.78K |
Adaptimmune Therapeutics News
- 11 days ago - Adaptimmune Announces Delisting from Nasdaq - Newsfile Corp
- 2 months ago - Adaptimmune Reports Q2 Financial Results and Provides Business Update - Newsfile Corp
- 3 months ago - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - Newsfile Corp
- 6 months ago - Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Adaptimmune Reports Q1 Financial Results and Provides Business Update - Newsfile Corp
- 6 months ago - Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 - Newsfile Corp
- 8 months ago - Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 8 months ago - Adaptimmune Provides Q4 and Full Year 2024 Business Update - Newsfile Corp